- Previous Close
48.00 - Open
55.00 - Bid --
- Ask --
- Day's Range
54.30 - 55.00 - 52 Week Range
40.85 - 71.90 - Volume
33,001 - Avg. Volume
2,783 - Market Cap (intraday)
1.062B - Beta (5Y Monthly) 0.71
- PE Ratio (TTM)
-- - EPS (TTM)
-2.53 - Earnings Date May 8, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus-induced cervical precancerous lesions. The company has a license agreement with Asieris MediTech Co to develop and commercialize Cevira; and a strategic agreement with Richard Wolf GmbH to develop and commercialize a 4K LED high-definition reusable blue light cystoscope based on Richard Wolf's System blue technology. It sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. The company operates in the Nordic countries, Germany, France, Austria, the United Kingdom, the Benelux, Italy, rest of the Europe, Canada, and the United States. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.
www.photocure.com99
Full Time Employees
December 31
Fiscal Year Ends
--
Sector
--
Industry
Recent News: 0IMT.L
View MorePerformance Overview: 0IMT.L
Trailing total returns as of 4/19/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0IMT.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0IMT.L
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-0.64%
Return on Assets (ttm)
1.76%
Return on Equity (ttm)
-0.68%
Revenue (ttm)
525.39M
Net Income Avi to Common (ttm)
-3.34M
Diluted EPS (ttm)
-2.53
Balance Sheet and Cash Flow
Total Cash (mrq)
288.83M
Total Debt/Equity (mrq)
3.35%
Levered Free Cash Flow (ttm)
39.08M